Supreme Pharma, which trades in the U.S. with an OTC listing, SPRWF, and on the CSE in Canada under SL, recently earned a license to cultivate medical cannabis in Canada under its MMPR program. I interviewed John Fowler, its President, and covered the following areas:

• John's background and the background of key officers and directors
• The history of the company and its AMMCan unit (which is the licensed entity)
• The business model
• AMMCan's hybrid grow facility
• The time-line to receiving a selling license
• The capital position of the company

John began working in the medical marijuana sector over ten years ago. He pursued a career in law to assist medical marijuana patients with legal challenges relating to access, employment and tenancies. This culminated in 2013 when John assisted with R v. Mernagh at the Ontario Court of Appeal. John is committed to providing Canadians access to high-quality, low-cost medical marijuana and working with the medical community to improve physician education and support for medical marijuana.

To learn more about Supreme, you can visit their website at http://www.Supreme.ca

Alan Brochstein, CFA has no personal stake in Supreme Pharma and received no compensation to conduct this interview on behalf of his subscribers at 420 Investor, though he includes SPRWF in one or more model portfolios. 420 Investor is a due diligence platform covering publicly-traded cannabis stocks.

To subscribe to 420 Investor and access its complete set of features, there are two options, including annual or monthly. 420 Investor also offers a monthly newsletter that includes a Canadian Cannabis model portfolio that is benchmarked against a proprietary index. The monthly newsletter includes three feature articles, a sector review and forward outlook, a calendar, a summary of key news for individual stocks on the Focus List (like Supreme) and a price performance table for those same stocks.